There is a need for more options in non-muscle invasive bladder cancer (NMIBC) when BCG fails1,2

Bacillus Calmette-Guérin (BCG) has remained the first-line standard of care for more than 40 years2,3

  • Though BCG can be initially effective in the first-line treatment of high-risk NMIBC, BCG will fail in more than 40% of patients4
  • When BCG fails, high-risk patients are more likely to progress to muscle-invasive diseases, bringing them one step closer to life-altering radical cystectomy5

The limited number of patients studied in these [therapeutic] trials, the modest and limited recurrence-free
survival with treatment, and the lack of data demonstrating an improvement in progression-free survival
illustrate the need for novel agents.5

– AUA/SUO Guideline

Support for Your Patients and Their Caregivers

Bladder Cancer Advocacy Network

The Bladder Cancer Advocacy Network (BCAN) is a community of patients, caregivers, survivors, advocates, medical and research professionals united in support of people touched by bladder cancer.

What would more options in this space
mean for your patients?

References: 1. Siddiaui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials in non-muscle invasive bladder cancer (NMIBC). Urol Oncol. 2017;35(8):516-527. 2. Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: intravesical treatments beyond bacille Calmette-Guérin. Cancer. 2017;123(3):390-400. 3. Lamm DL, Blumenstein BA, Crissman J D, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, TI and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000;163(4):1128-1129. 4. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009;27(34):5680-5684. 5. American Urological Association. (2020). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline (2020).

Copyright FerGene, Inc. 2020/11 US-URONC-2000010